Pfizer and Sangamo re-open PhIII of hemophilia A gene therapy; AEON headed to PhIII

A year after voluntarily pausing the Phase III study of their hemophilia A gene therapy program, and four months after FDA lifted the clinical hold, Pfizer and Sangamo Therapeutics say they will resume dosing next month.

The move pushes back the original data readout...

Click to view original post